November 17, 2021
18/11/2021
November 17, 2021
LA JOLLA, CA A combination of two highly potent antibodies, first discovered in the blood of ebolavirus survivors, protects monkeys against the three most medically important ebolavirus species, according to a new study from scientists at Vanderbilt University Medical Center (VUMC), Scripps Research, and Galveston National Laboratory. The antibody cocktail is the first to provide such broad protection, and potentially will be a powerful weapon against future ebolavirus outbreaks.
In the study, published October 28 in Cell, the scientists conducted extensive preclinical tests of the antibody cocktail, showing its effectiveness against not only the best-known ebolavirus species, Zaire ebolavirus (EBOV) sometimes called Ebola virus but also Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV). The three ebolaviruses in recent decades have caused frequent hemorrhagic fever outbreaks in Africa, killing tens of thousands of people.
The researchers used low-temperature electron microscopy (cryo-EM) to map the structures of the antibodies bound to their target sites on ebolaviruses, showing how they work in complementary ways to neutralize these pathogens.
The synergy between these two antibodies is really unique and adds up to broader protection than any other antibody or combination has shown so far, said study co-lead author Charles Murin, PhD, a staff scientist at Scripps Research.
Murin led the structural analysis, sharing co-lead authorship with Pavlo Gilchuk, PhD, a postdoctoral research associate at Vanderbilt. Murin works in the laboratory of study co-author Andrew Ward, PhD, professor in the Department of Integrative Structural and Computational Biology at Scripps Research. The study's lead investigator was James Crowe Jr., MD, professor of Pediatrics and Pathology, Microbiology and Immunology at VUMC, and director of the Vanderbilt Vaccine Center.
The high lethality of ebolaviruses and their potential for rapid spread has driven efforts to find effective vaccines and treatments, including antibody-based therapies that could be given, for example, to provide immediate, short-term protection for people who have been exposed to these viruses. However, the antibody therapies and vaccines that have been developed to date provide protection only against EBOV.
The remarkable antibodies described in the new study, rEBOV-442 and rEBOV-515, were derived from antibody-making B cells that researchers recovered from the blood of two survivors of African EBOV outbreaks during 2013 to 2016.
The researchers conducted a battery of tests showing that the two antibodies have neutralization activity against not only EBOV but also SUDV and BDBV, draw immune cells to kill ebolavirus-infected cells in two distinct ways, and, when combined in a therapeutic cocktail, enhance each other's efficacy to provide very potent neutralization of all three viral species. The experiments showed that ebolaviruses subjected to the 442/515 cocktail also were much less likely to evolve escape mutants compared to other antibody combinations.
The researchers injected macaque and cynomolgus monkeys with lethal doses of EBOV, SUDV, and BDBV, and then injected them with two doses of the antibody cocktail starting on day 3 to 6 after the viral exposure. The cocktail protected the monkeys not only from death but also from signs of disease even from abnormal blood-test results. By contrast, monkeys who were given the virus but not the antibody cocktail succumbed in 7 to 14 days.
Murin's cryo-EM-based structural studies supported the protection trials by revealing the two distinct locations where the antibodies bind to the ebolavirus outer glycoprotein. His results confirmed that the -515 antibody in particular binds to a small site that is uniquely well conserved among the EBOV, SUDV, and BDBV species.
That structural information was really valuable in understanding why these antibodies work so well and so broadly when combined, Murin says.
The very promising results are the apparent culmination of years of work toward the discovery of such a potent, broad-acting antibody cocktail, and set the stage for scaled-up production of the antibodies, and experimental trials in humans during future ebolavirus outbreaks.
Pan-ebolavirus protective therapy by two multifunctional human antibodies was co-authored by Pavlo Gilchuk, Seth Zost, Rachel Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, Robin Bombardi, Robert Carnahan, and James Crowe, Jr., of the Vanderbilt Vaccine Center; Charles Murin and Andrew Ward of Scripps Research; and Robert Cross, Philipp Ilinykh, Kai Huang, Natalia Kuzmina, Viktoriya Borisevich, Krystle Agans, Joan Geisbert, Alexander Bukreyev, and Thomas Geisbert of the Galveston National Laboratory.
The research was supported by the National Institutes of Health (U19 AI109711, U19 AI142785, U19 AI109762), the U.S. Department of Health and Human Services (HHSN272201400058C), the U.S. Defense Threat Reduction Agency (HDTRA1-13-1-0034), and Merck KGaA.
Infectious Diseases Integrative Structural & Computational Biology Ward, Andrew
LINK: | https://www.scripps.edu/news-and-events/press-room/2021/20211117-scrip... |
See more stories from scripps |
More from Scripps
20/04/2024
April 19, 2024
New copper-catalyzed C-H activation strategy from Scripps Research Two-mode reactions inspired by human detox enzymes offer powerful new tools for drug discover...
12/04/2024
April 11, 2024
Scripps Research chemists devise easier new method for making a common type of building block for drugs Scientists transform simple linear amines into saturated...
06/04/2024
April 05, 2024
A simple, inexpensive way to make carbon atoms bind together A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules,...
04/04/2024
April 03, 2024
Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first...
30/03/2024
March 29, 2024
How blocking a neural receptor responsible for addiction could reduce alcohol use A Scripps Research team found that a new therapeutic that targets the kappa op...
13/03/2024
March 13, 2024
New computational strategy boosts the ability of drug designers to target proteins inside the membrane Customized-design approach could streamline the design of...
29/02/2024
February 29, 2024
Scripps Research scientists reveal how first cells could have formed on Earth New phospholipid discovery brings researchers closer to understanding how primordi...
29/02/2024
February 28, 2024
How molecular handedness emerged in early biology Scripps Research chemists fill a major gap in origin-of-life theories. February 28, 2024 LA JOLLA, CA Mole...
22/02/2024
February 21, 2024
Snaking toward a universal antivenom Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms. February 21, 2024 ...
06/02/2024
February 06, 2024
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases AbbVie...
26/01/2024
January 25, 2024
Re-energizing mitochondria to treat Alzheimer's disease Scripps Research team restored neuron-to-neuron connections in human cells. January 25, 2024 LA JO...
24/01/2024
January 04, 2024
100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health For the last century, institute leaders and renowned scie...
23/01/2024
January 23, 2024
New technology lets researchers track brain cells' off switches The method could shed light on what goes awry in numerous brain conditions when neurons ar...
09/01/2024
January 08, 2024
Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines The ALSAM Foundation, founded by the Skaggs family, provides lasting g...
04/01/2024
January 03, 2024
Life science entrepreneur Gene Lay joins Scripps Research Board of Directors Lay, founder of the global biotech company BioLegend, brings invaluable experience ...
21/12/2023
December 20, 2023
Taming a plant-derived toxin Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments. ...
19/12/2023
December 18, 2023
Scripps Research Executive Vice President Eric Topol gives TED talk on transformative power of AI in medicine Topol provides an overview of how AI models can i...
13/12/2023
December 12, 2023
New AI-powered algorithm could better assess people's risk of common heart condition Early detection of atrial fibrillation can reduce the risk of stroke an...
07/12/2023
December 06, 2023
Nanoparticle flu vaccine design shows promise in early tests Scripps Research-designed vaccine could provide broad, enduring protection against influenza A str...
16/11/2023
November 15, 2023
Numerous Scripps Research scientists named Highly Cited Researchers Clarivate's annual, global list represents researchers who have demonstrated significant...
07/11/2023
November 06, 2023
Multiple sclerosis drug invented at Scripps Research slows long-term devastating disease progression Late-breaking data reinforces the effectiveness and safety ...
05/10/2023
October 04, 2023
Keren Lasker named a 2023 Moore Inventor Fellow The prestigious award will support Lasker's inventive research in membraneless organelles and their applica...
22/09/2023
September 21, 2023
Michael Bollong named a 2023 Amgen Young Investigator The prestigious award will support Bollong's research identifying new molecular targets and therapeuti...
09/09/2023
September 08, 2023
Philip Dawson receives 2024 American Chemical Society National Award Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational c...
07/09/2023
September 06, 2023
Scripps Research chemists devise a method for C-H activation of alcohols The method represents a new toolkit for making drugs and other compounds. September 06...
31/08/2023
August 30, 2023
Scripps Research receives $1.5M to surveil infectious disease threats in wastewater Bill & Melinda Gates Foundation award to support the development of multi-pa...
16/08/2023
August 16, 2023
How cold temperatures trigger the brain to boost appetite Scripps Research scientists' discovery could lead to new weight loss and metabolic health treatmen...
08/08/2023
August 07, 2023
Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study Scripps Research-developed antibody therapy...
04/08/2023
August 03, 2023
How sensory neurons impact the gut Scripps Research scientists show that the receptor PIEZO2 in sensory neurons controls gut motility and transit time, which a...
26/07/2023
July 26, 2023
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets The expanded strategic collaboration will advan...
23/07/2023
July 21, 2023
Scripps Research scientists develop AI-based tracking and early-warning system for viral pandemics Machine-learning system effectively predicts emergence of pro...
19/07/2023
July 19, 2023
Monitoring T cells may allow prevention of type 1 diabetes Scripps Research study shows that analyzing T cells in blood samples could be used to select at-risk ...
19/07/2023
July 18, 2023
Scripps Research mourns passing of leading organic chemist Albert Eschenmoser Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understa...
15/06/2023
June 14, 2023
Scripps Research awarded $46.8 million by NIH to promote human health through innovative translational science and training The Translational Institute is harne...
13/06/2023
June 13, 2023
Scripps Research's Danielle Grotjahn named 2023 Pew Scholar in the Biomedical Sciences The award will support Grotjahn's study of how cells assemble the...
31/05/2023
May 31, 2023
Crossing the ring: new method enables C-H activation across saturated carbocycles Scripps Research chemists add another powerful tool to their molecular editin...
24/05/2023
May 23, 2023
Scripps Research develops behind-the-scenes tool for better biomedical data discovery The new resource makes datasets more discoverable for life science communi...
19/05/2023
May 15, 2023
Scripps Research neuroscientist Hollis Cline elected to American Academy of Arts and Sciences Cline is recognized for her discoveries about the role of sensory ...
19/05/2023
May 18, 2023
Scripps Research's Skaggs Graduate School awards doctoral degrees to 31st graduating class Commencement ceremony will be livestreamed via Zoom and on instit...
13/05/2023
May 12, 2023
A better route to benzocyclobutenes, sought-after building blocks for drugs Scripps Research chemists devise a new, C-H activation-based method for the synthesi...
09/05/2023
May 08, 2023
Renowned Scripps Research professor Jeffery Kelly elected to National Academy of Sciences Kelly's groundbreaking work on protein misfolding has led to thera...
28/04/2023
April 27, 2023
Mirror-image molecules pave new path for cancer drug discovery By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps R...
22/04/2023
April 21, 2023
How alcohol consumption contributes to chronic pain A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and...
21/04/2023
April 20, 2023
Xin Jin receives dual awards to study autism risk genes in neurodevelopment Major grants from the National Institutes of Health and California Institute for Reg...
20/04/2023
April 19, 2023
Trim the sugar: New HIV vaccine design improves immune response Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA A...
18/04/2023
April 17, 2023
Therapeutic can seek and destroy potent opioid to treat overdoses Scripps Research chemists developed a new biologic to work against the synthetic opioid carfen...
07/03/2023
March 06, 2023
How heavy alcohol consumption increases brain inflammation The findings by a Scripps Research team point toward a potential new drug target for treating alcohol...
02/03/2023
March 01, 2023
Scientists find human antibodies that can block multiple coronaviruses including SARS-CoV-2 Results from a Scripps Research and UNC team pave the way for a vacc...
28/02/2023
February 28, 2023
$10 million grant funds Scripps Research Alcohol Research Center through its 50th year The five-year grant supports research into the neurobiology of alcohol us...
28/02/2023
February 27, 2023
Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilas...